Severe drug-related skin reaction: Toxic epidermal necrolysis caused by carbamazepine;Schwere arzneimittelinduzierte hautreaktion: Toxische epidermale nekrolyse durch carbamazepin

Klinische Padiatrie

Volumn 216, Issue 5, 2004, Pages 288-293

  Fischer, M ^a   Hamm, H ^a   Wirbelauer, Johannes ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Blister formation; Carbamazepine; Drug induced skin reaction; Toxic epidermal necrolysis

Indexed keywords

CARBAMAZEPINE;

ARTICLE; BLISTER; BULLOUS SKIN DISEASE; CASE REPORT; DIFFERENTIAL DIAGNOSIS; DRUG ERUPTION; DRUG INDUCED DISEASE; ERYTHEMA MULTIFORME; FOCAL EPILEPSY; HUMAN; ILIAC VEIN; MALE; RESPIRATORY FAILURE; SCHOOL CHILD; SEPSIS; STEVENS JOHNSON SYNDROME; SYMBLEPHARON; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TOXIC EPIDERMAL NECROLYSIS; VEIN THROMBOSIS;

ANTI-BACTERIAL AGENTS; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; DIAGNOSIS, DIFFERENTIAL; EPIDERMAL NECROLYSIS, TOXIC; EPILEPSIES, PARTIAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; TIME FACTORS;

EID: 4644255238     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-44896     Document Type: Article

References (39)

1. Bachot N, Roujeau J-C. Physiopathology and treatment of severe drug eruptions. Curr Opin Allergy Clin Immunol 2001; 1: 293-298
2. Bastuji-Garin S, Rzany B, Stern RS, Shear N, Naldi L, Roujeau J-C. Clinical classification of cases of Toxic Epidermal Necrolysis, Stevens-Johnson-Syndrome, and Erythema multiforme. Arch Dermatol 1993; 129: 92-96
3. Brady HR, Brenner BM. Acute Prenal Failure. In: Harrison's Priciples of internal medicine. 13th ed. McGraw-Hill 1994
4. Brettle RP. Erythema multiforme syndrome associated with varicella. N Engl J Med 1981; 305: 1472-1473
5. Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, Walker AM. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990; 126: 43-47
6. Dietrich A, Kawakubo Y, Rzany B, Mockenhaupt M, Simon JC, Schopf E. Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Exp Dermatol 1995; 4: 313-316
7. Doose H. Epilepsien im Kindesalter. 11. Aufl Hamburg Desition 1998
8. Forman R, Koren G, Shear NH. Erythema multiforme, Stevens-Johnson- Syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. Drug Saf 2002; 25: 965-972
9. Fournier S, Bastuji-Garin S, Mentec H, Revuz J, Roujeau JC. Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection. Eur J Clin Microbiol Infect Dis 1995; 14: 558-559
10. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136: 323-327
11. Ghislain PD, Roujeau J-C. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 2002; 8: 5
12. Guillaume JC, Roujeau JC, Revuz J, Penso D, Touraine R. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol 1987; 123: 1166-1170
13. Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204: 503-512
14. Hanakawa Y, Schechter NM, Lin C, Garza L, Li H, Yamaguchi T, Fudaba Y, Nishifuji K, Sugai M, Amagai M, Stanley JR. Molecular mechanisms of blister formation in bullous impetigo and staphylococcal scalded skin syndrome. J Clin Invest 2002; 110: 53-60
15. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233-243
16. Kauppinen K. Cutaneous reactions to drugs with special reference to severe bullous mucocutaneous eruptions and sulphonamides. Acta Derm Venereol 1972; 68 (Suppl): 1-89
17. Laibson PR. Current concepts and techniques in corneal transplantation. Curr Opin Ophthalmol 2002; 13: 220-223
18. Leititis JU, Burghard R, Rietschel E, Rieger CH, Brandis M. Stevens-Johnson syndrome during an immunosuppressive therapy with cyclophosphamide and prednisone. Klin Padiatr 1985; 197: 441 -442
19. Majumdar S, Mockenhaupt M, Roujeau J, Townshend A. Interventions for toxic epidermal necrolysis (Cochrane Review). Cochrane Database Syst Rev 2002; 4: CD001435
20. Mockenhaupt M, Norgauer J. Schwere arzneimittelinduzierte Hautreaktionen. Allergologie 2001; 24: 419-432
21. Nassif A, Bensussan A, Dorothee G, Mami-Chouaib F, Bachot N, Bagot M, Boumsell L, Roujeau JC. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002; 118: 728-733
22. Peng YZ, Yuan ZQ, Xiao GX. Effects of early enterai feeding on the prevention of enterogenic infection in severely burned patients. Burns 2001; 27: 145-149
23. Prandota J. Important role of prodromal viral infections responsible for inhibition of xenobiotic metabolizing enzymes in the pathomechanism of idiopathic Reye's syndrome, Stevens-Johnson syndrome, autoimmune hepatitis, and hepatotoxicity of the therapeutic doses of acetaminophen used in genetically predisposed persons. Am J Ther 2002; 9: 149-156
24. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, Mauri DN, Flynn K, Trent J, Margolis DJ, Saurat JH, French LE. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins. Arch Dermatol 2003; 139: 26-32
25. Revuz J, Penso D, Roujeau JC, Guillaume JC, Payne CR, Wechsler J, Touraine R. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123: 1160-1165
26. Roujeau J-C, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, Mockenhaupt M, Paoletti C, Shapiro S, Shear N, Schöpf E, Kaufman DW. Medication Use and the Risk of Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis. N Engl J Med 1995; 333: 1600-1608
27. Roujeau J-C. Treatment of SJS and TEN in Skin Reactions to Drugs. In: Kauppinen K, Alanko K, Hannuksela M, Maibach H (eds). Boca Raton USA CRC Press LLC 1998; 141-149
28. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999; 353: 2190-2194
29. Rzany B, Hering O, Mockenhaupt M, Schroder W, Goerttler E, Ring J, Schopf E. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 1996; 135: 6-11
30. Rzany B, Schmitt H, Schopf E. Toxic epidermal necrolysis in patients receiving glucocorticosteroids. Acta Derm Venereol 1991; 71: 171-172
31. Spies M, Sanford AP, Aili Low JF, Wolf SE, Herndon DN. Treatment of extensive toxic epidermal necrolysis in children. Pediatrics 2001; 108: 1162-1168
32. Tristani-Firouzi P, Petersen MJ, Saffle JR, Morris SE, Zone JJ. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002; 47: 548-552
33. van der Meer JB, Schuttelaar ML, Toth GG, Kardaun SH, Beerthuizen G, de Jong MC, Jonkman MF, Nieuwenhuis P. Successful dexamethasone pulse therapy in a toxic epidermal necrolysis (TEN) patient featuring recurrent TEN to oxazepam. Clin Exp Dermatol 2001; 26: 654-656
34. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-493
35. Wilkins J, Morrison L, White CR. Oculocutaneous manifestations of the erythema multiforme/Stevens-Johnson/toxic epidermal necrolysis spectrum. Dermatol Clin 1992; 10: 571-582
36. Wolkenstein P, Carriere V, Charue D, Bastuji-Garin S, Revuz J, Roujeau JC, Beaune P, Bagot M. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995; 5: 255-258
37. Wolkenstein P, Chosidow O, Flechet ML, Robbiola O, Paul M, Dume L, Revuz J, Roujeau JC. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 1996; 35: 234-236
38. Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, Maignan M, Schuhmacher MH, Milpied B, Pilorget A, Bocquet H, Brun-Buisson C, Revuz J. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352/9140 1565-1640
39. Wolkenstein P, Revuz J. Toxic epidermal necrolysis. Dermatol Clin 2000; 18: 485-495